Loading...
XNAS
APGE
Market cap2.43bUSD
Jul 25, Last price  
40.82USD
1D
-1.97%
1Q
10.77%
IPO
96.25%
Name

Apogee Therapeutics Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
Net income
0k
P
-39,785,000-83,985,0000
CFO
-171m
L+128.96%
-16,427,000-74,761,000-171,174,000

Profile

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
IPO date
Jul 14, 2023
Employees
25
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFY
2024‑122023‑122022‑12
Income
Revenues
Cost of revenue
216,870
93,003
30,727
Unusual Expense (Income)
NOPBT
(216,870)
(93,003)
(30,727)
NOPBT Margin
Operating Taxes
(18)
(34)
Tax Rate
NOPAT
(216,852)
(93,003)
(30,693)
Net income
(83,985)
111.10%
(39,785)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
493,483
315,391
168,317
BB yield
-19.74%
-0.05%
Debt
Debt current
3,234
2,202
Long-term debt
20,428
2,967
Deferred revenue
Other long-term liabilities
Net debt
(496,991)
(390,290)
(151,890)
Cash flow
Cash from operating activities
(171,174)
(74,761)
(16,427)
CAPEX
(1,152)
(167)
Cash from investing activities
(300,462)
(273,910)
Cash from financing activities
495,109
315,391
184
FCF
(227,582)
(95,597)
Balance
Cash
520,653
395,459
151,890
Long term investments
Excess cash
520,653
395,459
151,890
Stockholders' equity
(305,000)
(123,441)
(79,570)
Invested Capital
1,033,625
506,489
79,570
ROIC
ROCE
EV
Common stock shares outstanding
55,194
25,005,774
50,674
Price
45.30
62.13%
27.94
 
Market cap
2,500,287
-99.64%
698,661,326
 
EV
2,003,296
698,271,036
EBITDA
(216,681)
(93,003)
(30,727)
EV/EBITDA
Interest
9,150
Interest/NOPBT